Toniv,

Yes your memory is correct about that "250 patient" number for China. In Masila's June 30th special meeting transcript, Masila wrote, "Anywhere from 2400-4800 patients, dosing up to 2 yrs with average of 18 months. 250 of those likely in China territories with funding provided by Shenzen." Of course, nothing is definitive until the trial is announced and enrollment complete.

Sorry for depleting your ink. I'm a little long winded a lot of the time. :-)